| P2093 | author name string | John Laterra | |
| | David E Gerber | |
| P2860 | cites work | Genes expressed in human tumor endothelium | Q24290105 |
| | Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models | Q24629814 |
| | Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis | Q24683896 |
| | Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. | Q27824850 |
| | Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets | Q28140238 |
| | Improving the efficacy of antibody-based cancer therapies | Q28208361 |
| | Clinical impact and functional aspects of tenascin-C expression during glioma progression | Q28211100 |
| | Met, metastasis, motility and more | Q28235183 |
| | Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors | Q28295039 |
| | Molecular regulation of vessel maturation | Q29614540 |
| | Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis | Q29620559 |
| | EGFRvIII as a promising target for antibody-based brain tumor therapy | Q34157678 |
| | Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer | Q34323659 |
| | Intraventricular Immunotoxin Therapy for Leptomeningeal Neoplasia | Q48598762 |
| | Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: A phase II trial | Q48602872 |
| | Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas | Q48674565 |
| | Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates | Q48676851 |
| | Intratumoral infusion of the monoclonal antibody, mAb 425, against the epidermal-growth-factor receptor in patients with advanced malignant glioma | Q48712757 |
| | Safety and feasibility of convection-enhanced delivery of Cotara for the treatment of malignant glioma: initial experience in 51 patients | Q48883553 |
| | Disruption of intracerebral progression of C6 rat glioblastoma by in vivo treatment with anti-CD44 monoclonal antibody | Q52537485 |
| | MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. | Q55470198 |
| | Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial. | Q55470352 |
| | Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. | Q55470691 |
| | Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric study. | Q55477123 |
| | The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy | Q34325749 |
| | Arming antibodies: prospects and challenges for immunoconjugates | Q34449555 |
| | Human telomere reverse transcriptase expression predicts progression and survival in pediatric intracranial ependymoma | Q34507174 |
| | Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption | Q34997337 |
| | Vascular gene expression in nonneoplastic and malignant brain. | Q35103013 |
| | Classification of glioblastoma multiforme in adults by molecular genetics | Q35144463 |
| | Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors | Q35162055 |
| | Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: growth factor and Ras signaling pathways | Q35576159 |
| | Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis | Q35641225 |
| | A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity | Q35660849 |
| | Targeted radiotherapy of brain tumours | Q35745251 |
| | Monoclonal antibodies for brain tumour treatment | Q35873775 |
| | Progress report on the potential of angiogenesis inhibitors for neuro-oncology | Q35964419 |
| | Treatment of recurrent and cystic malignant gliomas by a single intracavity injection of 131I monoclonal antibody: feasibility, pharmacokinetics and dosimetry | Q35975895 |
| | Designing antibodies for oncology | Q36366536 |
| | Antibodies and their fragments as anti-cancer agents | Q36384951 |
| | VEGF inhibitors in cancer therapy | Q36384960 |
| | Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents | Q36395924 |
| | Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours | Q36400537 |
| | Molecular biology of epidermal growth factor receptor inhibition for cancer therapy | Q36481002 |
| | Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study | Q36643720 |
| | Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease | Q37118356 |
| | Distribution of labelled anti-tenascin antibodies and fragments after injection into intact or partly resected C6-gliomas in rats | Q39695964 |
| | Targeting of the receptor protein tyrosine phosphatase beta with a monoclonal antibody delays tumor growth in a glioblastoma model | Q40314272 |
| | Immunotoxin treatment targeted to the high-molecular-weight melanoma-associated antigen prolonging the survival of immunodeficient rats with invasive intracranial human glioblastoma multiforme | Q40566621 |
| | Direct Injection of 90Y MoAbs into Glioma Tumor Resection Cavities Leads to Limited Diffusion of the Radioimmunoconjugates into Normal Brain Parenchyma: A Model to Estimate Absorbed Radiation Dose | Q40864219 |
| | Scatter factor promotes motility of human glioma and neuromicrovascular endothelial cells | Q41071769 |
| | Human glioma-specific antigens detected by monoclonal antibodies | Q41630487 |
| | Human antiglioma monoclonal antibodies from patients with astrocytic tumors | Q41631779 |
| | Inhibition of cell growth and tumorigenesis of human glioblastoma cells by a neutralizing antibody against human basic fibroblast growth factor | Q41983673 |
| | Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: preliminary study | Q43631352 |
| | 131I radioconjugated antibodies for the locoregional radioimmunotherapy of high-grade malignant glioma--phase I and II study | Q43808450 |
| | Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo | Q46067245 |
| | Complement activation determines the therapeutic activity of rituximab in vivo. | Q47745204 |
| | Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malig | Q48133104 |
| | Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma | Q48136909 |
| | Efficacy of direct intratumoral therapy with targeted protein toxins for solid human gliomas in nude mice | Q48164496 |
| | Radioimmunoscintigraphy of intracranial glioma xenograft with a technetium-99m-labeled mouse monoclonal antibody specifically recognizing type III mutant epidermal growth factor receptor | Q48238155 |
| | Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin | Q48238648 |
| | Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma | Q48291216 |
| | Expression of tenascin in human gliomas: its relation to histological malignancy, tumor dedifferentiation and angiogenesis | Q48391355 |
| | (131)I-chTNT-1/B mAb: tumour necrosis therapy for malignant astrocytic glioma | Q48586802 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | monoclonal antibody | Q422248 |
| P304 | page(s) | 477-494 | |
| P577 | publication date | 2007-04-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Expert Opinion on Investigational Drugs | Q5421208 |
| P1476 | title | Emerging monoclonal antibody therapies for malignant gliomas | |
| P478 | volume | 16 | |